Osmotica Pharmaceutical
As of the edition of 20 October 2026, Osmotica Pharmaceutical runs 5 drugs, 5 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Osmotica Pharmaceutical was bankrupt in 2023.
The records place 2 company names in this family.
- Osmotica Pharmaceutical US LLC: bankrupt in 2023
Drugs by status
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methylphenidate | none listed | 11 |
| Venlafaxine | none listed | 1 |
| Desvenlafaxine | Ends 2027 (patent) | 0 |
| Omega-3-acid ethyl esters | none listed | 0 |
| Amantadine | none listed | 0 |
A route B row is one company at one target.